Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.

Positive

• Upcoming financial results report on March 15, 2022.
• Conference call to provide insights into business performance.

Negative

• None.

News Market Reaction – ALT

+1.27%

+1.27% Session move

In the trading session that priced this news, ALT gained 1.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update.

Conference Call Information:
Date: Time: Domestic Dial-in: International Dial-in: Conference ID: Webcast:	Tuesday, March 15 8:30 am Eastern Time (844) 615-6509 (918) 922-3148 4557398 https://edge.media-server.com/mmc/p/5www3cgz

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

When will Altimmune report its Q4 and full year 2021 financial results?

Altimmune will report its financial results on March 15, 2022.

What time is Altimmune's conference call on March 15, 2022?

The conference call is scheduled for 8:30 AM ET.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide (ALT-801), for treating obesity and NASH.

What other therapeutic is Altimmune developing?

In addition to pemvidutide, Altimmune is developing HepTcell™, aimed at chronic hepatitis B.